Business Wire

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

9.4.2022 15:08:00 EEST | Business Wire | Press release

Share

Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting. Rhizen’s poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor (RP7214) in AML.

Rhizen had earlier indicated that its PARP program had demonstrated differentiated IND enabling preclinical safety. The additional preclinical data being presented at AACR 2022 suggests that this differentiated safety may be due to the lower bone marrow distribution of RP12146 and concomitantly lower haematological toxicity. “We believe RP12146’s safety differential has allowed us to progress through the dose escalation study more efficiently. Further, the emerging data from our ongoing phase 1 dose escalation study is encouraging & corroborative with robust target engagement and safety observed so far. We believe that this differentiation, as it translates more fully in the clinic, may allow us to explore the full potential of PARP inhibition across indications given RP12146’s potentially wide therapeutic window,” said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma.

Rhizen indicated that its DHODH inhibitor, RP7214 has robust activity as a single agent in inducing tumor volume & size reduction and differentiation of AML blasts consistent with its mechanism of action. RP7214 also potentiates the activity of standard of care AML agents such as cytarabine, venetoclax and azacytidine. Swaroop added that “We have initiated a phase 2 study to explore RP7214 in combination with azacytidine in relapsed/refractory AML, CMML and MDS patients. The potential of DHODH inhibition as a therapeutic modality in AML remains unfulfilled and we expect RP7214 can eventually realize that potential. We believe elderly patients who are ineligible for frontline chemotherapy and maintenance settings represent areas of unmet need that RP7214 can address.”

Details on Rhizen Pharma’s posters at AACR are as follows:

  1. Abstract Number: 1762
    Title: Activity of RP7214, a novel, selective, and potent small molecule inhibitor of DHODH, in AML
    Session: Small Molecule Therapeutic Agents
    Poster Number: 5492
  2. Abstract Number: 1766
    Title: Activity of RP12146, a novel, selective, and potent small molecule inhibitor of PARP 1/2, in solid tumors
    Session: Small Molecule Therapeutic Agents
    Poster Number: 5493

About Rhizen Pharmaceuticals AG.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.

Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kδ & CK1ε asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Rhizen is also developing Tenalisib, a unique dual PI3K-δ/γ & SIK3 inhibitor with a robust safety profile and promising activity in metastatic breast cancer and T-Cell lymphoma indications. Behind these assets, Rhizen has a deep oncology & inflammation pipeline spanning discovery to clinical development stages.

Rhizen is headquartered in Basel, Switzerland. For additional information, please visit https://www.rhizen.com/

Safe Harbor

This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rhizen Pharmaceuticals AG - Contact:
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

teamLab Biovortex Kyoto to Open ' Teahouse in a Sea of Light ' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 08:00:00 EET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

CORRECTING and REPLACING Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally19.11.2026 23:11:00 EET | Press release

This announcement replaces the release dated November 17, 2026 with the following version: J.P. Morgan Payments was added to the subhead and after the 11th paragraph. Multimedia was also updated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ Visa Agentic Ready Acceptance Partners The updated release reads: VISA EXPANDS AGENTIC READY TO HELP SCALE TRUSTED AI COMMERCE GLOBALLY Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, J.P. Morgan Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem. Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commer

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release

When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release

North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye